Harmony Biosciences Holdings (HRMY) Total Liabilities (2019 - 2026)
Harmony Biosciences Holdings (HRMY) posted Total Liabilities of $361.5 million for Q1 2026, down 9.95% sequentially from $401.4 million in Q4 2025, and up 7.9% YoY from $335.0 million in Q1 2025.
Harmony Biosciences Holdings (HRMY) Total Liabilities (2019 - 2026) Analysis & Trends
Harmony Biosciences Holdings has reported Total Liabilities for 8 years, with the latest figure at $361.5 million in Q1 2026.
- Quarterly Total Liabilities rose 7.9% year-over-year to $361.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $361.5 million (up 7.9% YoY) and the FY2025 annual result came in at $401.4 million, up 18.05% from the prior year.
- Total Liabilities declined to $361.5 million in Q1 2026 per HRMY's latest filing, from $401.4 million in the prior quarter.
- Over five years, Total Liabilities peaked at $401.4 million in Q4 2025 and troughed at $249.5 million in Q1 2022.
- A 5-year average of $317.4 million and a median of $331.3 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Liabilities increased 27.09% in 2023, then slipped 1.28% in 2024.
- Over 5 years, Total Liabilities stood at $271.0 million in 2022, then climbed by 27.09% to $344.5 million in 2023, then retreated by 1.28% to $340.0 million in 2024, then increased by 18.05% to $401.4 million in 2025, then retreated by 9.95% to $361.5 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $361.5 million, $401.4 million, and $373.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn | 373.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 373.84 Mn |
| Mar 31, 2026 | 361.48 Mn |
| Dec 31, 2025 | 401.41 Mn |
| Sep 30, 2025 | 373.10 Mn |
| Jun 30, 2025 | 334.93 Mn |
| Mar 31, 2025 | 335.01 Mn |
| Dec 31, 2024 | 340.05 Mn |
| Sep 30, 2024 | 331.33 Mn |
| Jun 30, 2024 | 319.80 Mn |
| Mar 31, 2024 | 331.59 Mn |
| Dec 31, 2023 | 344.46 Mn |
| Sep 30, 2023 | 296.43 Mn |
| Jun 30, 2023 | 275.01 Mn |
| Mar 31, 2023 | 272.05 Mn |
| Dec 31, 2022 | 271.03 Mn |
| Sep 30, 2022 | 299.58 Mn |
| Jun 30, 2022 | 258.50 Mn |
| Mar 31, 2022 | 249.50 Mn |
| Dec 31, 2021 | 246.94 Mn |
| Sep 30, 2021 | 239.07 Mn |